Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2005-03-29
2005-03-29
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S093210, C424S093300, C424S278100, C435S320100, C435S455000
Reexamination Certificate
active
06872385
ABSTRACT:
Disclosed are methods and compositions useful in the recruitment, activation and initiation of proliferation of immune cells. The instant invention relates to the discovery that specific insect cells and insect cell compositions exhibit adjuvant properties. The added benefit of this system is that the insect cells utilized may be transformed with an expression system and thus proteins may be introduced into the composition through direct protein expression by the cells. The claimed compositions and methods are particularly relevant in anti-tumor and cancer therapy. Of specific interest is the ability of the compositions of the invention to elicit a response that controls not only the primary tumor but also any metastatic cells or metastatic tumors which subsequently arise.
REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4745051 (1988-05-01), Smith et al.
patent: 4879236 (1989-11-01), Smith et al.
patent: 5077214 (1991-12-01), Guarino et al.
patent: 5098702 (1992-03-01), Zimmerman et al.
patent: 5155037 (1992-10-01), Summers
patent: 5162222 (1992-11-01), Guarino et al.
patent: 5169784 (1992-12-01), Summers et al.
patent: 5278050 (1994-01-01), Summers
patent: 5498540 (1996-03-01), Sawyer et al.
patent: 5681562 (1997-10-01), Sobol et al.
patent: 5759809 (1998-06-01), Iatrou
patent: 6224882 (2001-05-01), Smith et al.
patent: WO 8901038 (1989-02-01), None
patent: WO 9307906 (1993-04-01), None
patent: WO 9825574 (1998-06-01), None
patent: WO 9924049 (1999-05-01), None
patent: WO 0020561 (2000-04-01), None
patent: WO 0055345 (2001-09-01), None
Ayres et al., “The Complete DNA Sequence ofAutographa californicaNuclear Polyhedrosis Virus,”Virology202:586-605, 1994.
Bernards, et al., “Effective Tumor Immunotherapy Directed Against An Oncogene-Encoded Product Using A Vaccinia Virgus Vector,”Proc. Nat'l Acad. Sci. USA,84:6854-6858, 1987.
Blissard and Rohrmann, “Location, Sequence, Transcriptional Mapping, and Temporal Expression of the gp64 Envelope Glycoprotein Gene of theOrgyia pseudotsugataMulticapsid Nuclear Polyhedrosis Virus,” Virology 170:537-555, 1989.
Blissard and Rohrmann, “Baculovirus Diversity and Molecular Biology,”Annu. Rev. Entomol.35:127-155, 1990.
Carson et al., “Functional Mapping of an AcNPV Immediately Early Gene Which Augments Expression of the IE-1trans-Activated 39K Gene,”Virology,162:444-451, 1988.
Carson et al., “Transient Expression of theAutographa californicaNuclear Polyhedrosis Virus Immediate-Early Gene, IE-N, Is Regulated by Three Viral Elements,”J. Virol.,65:945-951, 1991.
Charlton and Volkman, “Penetration ofAutographa californicaNuclear Polyhedrosis Virus Nucleocapsids into IPLB Sf 21 Cells Induces Actin Cable Formation,” Virology, 197, 245-254, 1993.
DeGiovanni et al., Immunological and Non-Immunological Influence of H-2KbGene Transfection On The Metastatic Ability of B16 Melanoma Cells,Int. J. Cancer,48:270-276, 1991.
Dinney et al., “Inhibition of Basic Fibroblast Growth Factor Expression, Angiogensis, and Growth of Human Bladder Carcinoma in Mice by Systemic Interferon-α Administration,”Cancer Res.,58: 808-814, 1998.
Dong et al., “Suppression Of Tumorigenicity And Metastasis In Murine UV-2237 Fibrosarcoma Cells By Infection With A Retroviral Vector Harboring The Interferon-Beta Gene,”Cancer Immuno. Immunother.,46: 137-146, 1998.
Dong et al., “Suppression of Angiogenesis, Tumorigenicity, and Metastasis by Human Prostate Cancer Cells Engineered to Produce Interferon-β,”Cancer Res.,59: 872-879, 1999.
Dranoff et al., “Vaccination With Irradiated Tumor Cells Engineered To Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, And Long-Lasting Anti-Tumor Immunity,”Proc. Nat'l Acad. Sci. USA,90:3539-3543, 1993.
Einhorn and Grander, “Why do so many cancer patients fail to respond to interferon therapy?”J. Interferon and Cytokine Res.,16:275-281, 1996.
Elliott et al., “Perspectives on the Role of MHC Antigens in Normal and Malignant Cell Development,”Adv. Cancer Res.,53:181-245, 1989.
Estin et al., “Recombinant Vaccinia Virus Vaccine Against The Human Melanoma Antigen P97 For Use In Immunotherapy,”Proc. Nat'l Acad. Sci. USA,85: 1052-1056, 1988.
Fabra et al., “Modulation Of The Invasive Phenotype Of Human Colon Carcinoma Cells By Organ Specific Fibroblasts Of Nude Mice,”Differentiation,52: 101-110, 1992.
Fidler, “Critical determinants of cancer metastasis: rationale for therapy,”Cancer Chemother. Pharmacol.,43 suppl:S3-S10, 1999.
Flannery and Sandy, “Aggrecan catabolism in cartilage: Studies on the nature of a novel proteinase (aggrecanase) which cleaves the Glu373-Ala374 bond of the interglobular domain,” 39thAnnulal Meeting of Orthopaedic Research Society, p. 190, 1993.
Gariglio et al., “Therapeutic uterine-cervix cancer vaccines in humans,”Arch. Med. Res.,29:279-284, 1998.
Gohji et al., “Regulation of Gelatinase Production in Metastatic Renal Cell Carcinoma by Organ-specific Fibroblasts,”Jpn. J. Cancer Res.,85: 152-160, 1994a.
Gohji et al., “Human Recombinant Interferons-Beta and -Gamma Decrease Gelatinase Production and Invasion by Human KG-2 Renal-Carcinoma Cells,”Int. J. Cancer,58: 380-384, 1994b.
Groner, “Specificity and Safety of Baculoviruses,” In:The Biology of Baculoviruses,R.R. Granados and B.A. Federici (Eds.), CRC Press, Boca Raton, FL., pp. 177-202, 1986.
Guarino and Smith, “Nucleotide Sequence and Characterization of the 39K Gene Region ofAutographa californicaNuclear Polyhedrosis Virus,” Virology, 179:1-8, 1990.
Guarino and Summers, “Nucleotide Sequence and Temporal Expression of a Baculovirus Regulatory Gene,”J. Virol.,61:2091-2099, 1987.
Guarino et al., “Complete Sequence and Enhancer Function of the Homologous DNA Regions ofAutographa californicaNuclear Polyhedrosis Virus,”J. Virol.,60:224-229, 1986.
Guarino et al., “Ubiquitin Is Attached to Membranes of Baculovirus Particles by a Novel Type of Phospholipid Anchor,”Cell,80:301-309, 1995.
Hooft van Iddekinge et al., “Nucleotide Sequence of the Polyhedrin Gene ofAutographa californicaNuclear Polyhedrosis Virus,” Virology, 131:561-565, 1983.
Hu et al., “Characterization of a Recombinant Vaccinia Virus Expressing Human Melanoma-Associated Antigen p97,”J. Virol.,62: 176-180, 1988.
Kaufman et al., “A Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen (CEA),”Int. J. Cancer,48:900-907, 1991.
Kim and Cohen., “MHC Antigen Expression by Melanomas Recovered from Mice treated with Allogeneic Mouse Fibroblasts Genetically Modified for Interleukin-2 Secretion and the Expression of Melanoma-Associated Antigens,”Cancer Immunol. Immunother.,38:185-193, 1994.
Kozuma and Hakuhara, “Fusion Characteristics of a Nuclear Polyhedrosis Virus in Cultured Cells: Time Course and Effect of a Synergistic Factor and pH,”J. Invert. Pathol.,63:63-67, 1994.
Kuzio et al., “Nucleotide Sequence of the p10 Polypeptide Gene ofAutographa californicaNuclear Polyhedrosis Virus,” Virology, 139:414-418, 1984.
Lu et al., “Eradication of primary tumors and induction of systemic immunity by an intralesional injection of baculovirus system-mediated interferon-beta gene therapy,” Abstract,Proc. Amer. Assoc. Cancer Res. Ann. Meeting,41:470, 2000.
Lu et al., “Insect cells transduced with a baculoviral vector encoding murine interferon-β as a novel therapeutic cancer vaccine,” Abstract,UT MD Anderson Cancer Center, Houston, TX.
Martignoni et al., “Baculovirus ofAutographa californica(Lepidoptera: noctuidae): a Candidate Biological Control Agent for Douglas-Fir Tussock Moth (Lepidoptera: lymantriidae),” J.Econ. Entomol.,75:1120-1124, 1982.
McCluskie et al., “Route and method of del
Dong Zhongyun
Fidler Isaiah J.
Lu Weixin
Board of Regents , The University of Texas System
Fulbright & Jaworski
Guzo David
Nguyen Quang
LandOfFree
Adjuvant preparation for the induction of specific immunity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adjuvant preparation for the induction of specific immunity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant preparation for the induction of specific immunity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3372507